Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Exantide with Dapagliflozin · 1 trial · 1 indication
To compare the change from baseline to Week 28 in HbA1c between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.
| Arm | Type | Description |
|---|---|---|
| Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg | EXPERIMENTAL | - |
| Exenatide Once Weekly 2 mg Alone | EXPERIMENTAL | - |
| Dapagliflozin Once Daily 10 mg Alone | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Exantide with Dapagliflozin | DRUG | 2 mg weekly suspension injection and 10 mg Dapagliflozin |
| Exentide | DRUG | 2 mg |
| Dapagliflozin | DRUG | 10 mg once daily Dapagliflozin |
Inclusion criteria * Has a diagnosis of T2DM. * Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2. * Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to Screening. Exclusion criteria * FPG ≥280 mg/dL (15.6 mmol/L). * Serum calcitonin concentration ≥40 p...
Exantide with Dapagliflozin is an investigational combination therapy being developed by AstraZeneca PLC for the treatment of Diabetes Mellitus. It pairs a peptide-based agent with dapagliflozin and has been studied in a Phase 3 clinical trial. The combination remains in clinical development and is not described as approved.
Exantide with Dapagliflozin is being studied for the treatment of Diabetes Mellitus. The Phase 3 trial evaluated the combination in adults with this condition. It is an investigational therapy, and its use is limited to clinical research at this stage.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of Exantide with Dapagliflozin. The company is responsible for the clinical program evaluating this combination therapy in Diabetes Mellitus.
Exantide with Dapagliflozin is in Phase 3 development. One Phase 3 trial has been completed, and no active trials are currently listed. The therapy remains investigational and has not been described as approved.
Exantide with Dapagliflozin has been studied in one completed Phase 3 trial, NCT02229396. This randomized, double-blind, active-controlled study enrolled 695 participants across the United States, Hungary, Poland, Romania, Slovakia, and South Africa, and included 28-week, 24-week, and 52-week extension phases.